NCT06128330View on ClinicalTrials.gov

Point-of-care Measurement of the Antifibrinolytic Activity of Tranexamic Acid in Cardiac Surgery

PHASE4RecruitingINTERVENTIONAL
Enrollment

322

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Antifibrinolytic Agents
Interventions
DRUG

Tranexamic acid bolus 20 mg/kg

Bolus of tranexamic acid in the standard dose group

DRUG

Tranexamic acid bolus 10 mg/kg

Bolus of tranexamic acid in the low dose group

DRUG

Tranexamic acid bolus 1 mg/kg

Bolus of tranexamic acid in the low dose group (to add into the CPB prime)

DRUG

Tranexamic acid continuous infusion of 1 mg/kg/h in the low dose group

Tranexamic acid continuous infusion during the procedure

Trial Locations (1)

3010

RECRUITING

Dpt. Anesthesiology and pain Medicine, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER